Erik Olsson
PhD student at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Henrik Lindman
- E-mail:
- erikjohan.olsson@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ing 100/101, plan 1
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ing 100/101
751 85 Uppsala
Publications
Recent publications
-
Part of Clinical and Translational Radiation Oncology, 2027
- DOI for PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
- Download full text (pdf) of PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
-
Part of The Breast, 2025
- DOI for Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
- Download full text (pdf) of Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
-
Part of The Breast, 2025
-
Part of ESMO Real World Data and Digital Oncology, 2024
- DOI for Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
- Download full text (pdf) of Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
All publications
Articles in journal
-
Part of Clinical and Translational Radiation Oncology, 2027
- DOI for PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
- Download full text (pdf) of PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy – a retrospective single-centre experience
-
Part of The Breast, 2025
- DOI for Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
- Download full text (pdf) of Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
-
Part of The Breast, 2025
-
Part of ESMO Real World Data and Digital Oncology, 2024
- DOI for Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study
- Download full text (pdf) of Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study